Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STIMATE vs DDAVP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desmopressin acetate is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). It acts as a V2 receptor agonist in the renal collecting ducts, increasing water permeability and promoting water reabsorption, thereby reducing urine output. It also increases plasma levels of von Willebrand factor and factor VIII via V2 receptor stimulation on endothelial cells.
Synthetic analog of vasopressin; primarily activates V2 receptors in renal collecting ducts, increasing water reabsorption and concentrating urine.
Central diabetes insipidus,Primary nocturnal enuresis,Hemophilia A with factor VIII levels >5%,von Willebrand disease (type 1)
Central diabetes insipidus,Nocturnal enuresis,Hemophilia A,von Willebrand disease (type I)
Intranasal: 1 spray (1.5 mg) into one nostril, 1 hour prior to voiding or on awakening for bedwetting; maximum 2 sprays per day.
Central diabetes insipidus: 0.1-0.4 mg orally every 12-24 hours or 0.5-1 mcg subcutaneously/intranasally every 12-24 hours. Nocturnal enuresis: 0.2-0.4 mg orally at bedtime. Hemophilia A/von Willebrand disease: 0.3 mcg/kg intravenous over 15-30 minutes or 300 mcg subcutaneously or 150 mcg intranasally (for >50 kg).
Terminal elimination half-life is approximately 3-4 hours in healthy adults, but may be prolonged in patients with renal impairment or in older adults.
Terminal elimination half-life: 2-3 hours (intravenous); 3.4-4.4 hours (oral); clinical context: antidiuretic effect persists longer (6-20 hours) due to receptor binding.
Not extensively metabolized; primarily excreted unchanged in urine. A small fraction may be metabolized by liver or kidney peptidases.
Not significantly metabolized; primarily renal excretion.
Desmopressin is primarily excreted renally, with approximately 60-70% of the dose recovered unchanged in urine within 24 hours. The remaining fraction is metabolized hepatically and eliminated via feces.
Primarily renal (unchanged drug); >90% eliminated by kidneys.
Desmopressin exhibits low protein binding, approximately 1-2%, primarily to albumin.
50%; binding proteins: predominantly albumin.
Volume of distribution is 0.2-0.4 L/kg, indicating distribution primarily in extracellular fluid.
0.3 L/kg; indicates distribution primarily in extracellular fluid.
Intranasal: 10-20%; Oral: 5-10% due to extensive first-pass metabolism.
Intranasal: 10-20%; oral: 0.1-0.5% (sublingual tablets); subcutaneous: 100% (absolute bioavailability).
No specific adjustment; caution in severe impairment (e GFR <15 m L/min).
Not recommended if GFR <50 m L/min; use with caution if GFR 50-90 m L/min. No standard dose adjustment available; risk of water intoxication increases in renal impairment.
No specific adjustment; limited data in Child-Pugh C; use cautiously.
No dose adjustment recommended based on Child-Pugh class. Use with caution in severe hepatic impairment due to potential for fluid overload.
Children ≥6 years: same as adult; intranasal 1 spray (1.5 mg) 1 hour before bedtime. Do not exceed 2 sprays per day.
Central diabetes insipidus: 0.05-0.1 mg orally every 12-24 hours (titrate). Nocturnal enuresis: 0.2-0.4 mg orally at bedtime (age ≥6 years). Hemophilia A/v WD: 0.3 mcg/kg intravenous over 15-30 minutes; intranasal dose: 150 mcg (if ≤50 kg) or 300 mcg (if >50 kg); subcutaneous: 0.3 mcg/kg.
Use caution due to risk of hyponatremia and hypertension; start at lowest effective dose.
Start at lower end of dosing range (e.g., 0.1 mg orally once daily). Monitor serum sodium and fluid balance closely due to increased risk of hyponatremia and renal impairment.
No FDA black box warning exists for STIMATE.
None
Hyponatremia and fluid overload with water intoxication,Seizures due to hyponatremia,Thrombotic events (in patients with predisposing factors),Caution in patients with cystic fibrosis, coronary artery disease, or hypertension,Risk of arterial or venous thrombosis, especially with desmopressin treatment for bleeding disorders,Elderly patients at increased risk of hyponatremia
Risk of hyponatremia,Fluid intake restriction to avoid water intoxication,Seizures in severe hyponatremia,Cardiovascular disease caution (hypertension, coronary artery disease)
Hypersensitivity to desmopressin or any component,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Known platelet-type von Willebrand disease (pseudo-von Willebrand disease),Unstable angina, decompensated heart failure, or severe coronary artery disease
Hypersensitivity to desmopressin or components,Moderate to severe renal impairment (Cr Cl < 50 m L/min),Type IIB or platelet-type von Willebrand disease,Severe hyponatremia
No specific food interactions. However, avoid excessive fluid intake (more than needed to satisfy thirst) while taking STIMATE to reduce risk of water intoxication and hyponatremia. For patients with nocturnal enuresis, restrict fluids 1 hour before bedtime.
Avoid excessive water intake while on DDAVP. Do not consume grapefruit or grapefruit juice, as it may affect drug metabolism. Limit caffeine intake due to diuretic effects that could counteract DDAVP. Avoid high-sodium foods that may increase thirst and fluid intake.
Pregnancy Category X. Desmopressin (STIMATE) is contraindicated in pregnancy due to risk of uterine contractions and potential fetal harm. First trimester: No adequate studies; theoretical risk of teratogenicity. Second trimester: Avoid due to risk of preterm labor. Third trimester: May induce premature labor; use only if clearly needed for diabetes insipidus.
Category B: No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; risk cannot be excluded. Second and third trimester: No reported fetal harm, but avoid in preeclampsia due to antidiuretic effect.
Desmopressin is excreted in breast milk in low amounts; M/P ratio not established. No adverse effects reported in infants. Use with caution, especially in nursing mothers with preeclampsia due to potential for water intoxication.
Excreted in breast milk in low amounts (M/P ratio unknown). No adverse effects reported in infants; consider risk-benefit for maternal indication.
Increased plasma volume and enhanced renal clearance in pregnancy may reduce desmopressin concentrations; dose adjustments may be required. Monitor clinical response and adjust dose based on urine output and plasma sodium. No standard dose adjustment; individualize therapy.
Volume expansion and increased renal clearance in pregnancy may require dose adjustment; no standard guidelines. For diabetes insipidus, monitor urine output and serum sodium to titrate dose. Avoid in preeclampsia.
STIMATE (desmopressin acetate) is a synthetic analog of vasopressin used for diabetes insipidus and nocturnal enuresis. Monitor for hyponatremia, especially in patients with increased fluid intake, elderly, or those on medications that increase ADH (e.g., SSRIs, NSAIDs). Use with caution in patients with renal impairment, cardiovascular disease, or cystic fibrosis. Avoid use in patients with primary polydipsia or uncontrolled hypertension. For nocturnal enuresis, limit fluid intake 1 hour before dose. Start at lowest effective dose and titrate. Can be administered intranasally, orally, or intravenously. Intranasal route is not recommended for infants due to variable absorption.
DDAVP (desmopressin) is a synthetic analog of vasopressin with selective V2 receptor activity, minimizing vasoconstrictor effects. Administer intranasally for central diabetes insipidus; IV for hemophilia A and von Willebrand disease (type I). Monitor serum sodium closely, especially in elderly and young children, due to risk of hyponatremia and water intoxication. Avoid in patients with habitual psychogenic polydipsia. Can be used for nocturnal enuresis, but restrict fluid intake 1 hour before and 8 hours after dose to prevent hyponatremia.
Take STIMATE exactly as prescribed; do not increase dose or frequency without consulting your doctor.,For nocturnal enuresis: avoid drinking fluids 1 hour before bedtime and use the bathroom before going to sleep.,Report signs of hyponatremia: headache, nausea, vomiting, confusion, muscle cramps, weakness, or seizures.,Do not use STIMATE if you have allergies to desmopressin or any ingredient in the formulation.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease, heart disease, or cystic fibrosis.,Store STIMATE at room temperature away from moisture and heat; do not freeze.,For intranasal spray: prime the pump before first use and when not used for 7 days. Blow nose gently before use and do not sniff deeply after spraying.,Do not share your medication with others.
Take DDAVP exactly as prescribed; do not increase dose without consulting your doctor.,Limit fluid intake while using DDAVP to avoid severe low sodium levels (hyponatremia).,Monitor for symptoms of hyponatremia: headache, nausea, vomiting, confusion, lethargy, muscle cramps.,For nasal spray, do not blow nose for 30 minutes after administration.,Report any weight gain, persistent headache, or change in urination pattern to your healthcare provider.,Do not drink alcohol, as it may increase the risk of hyponatremia.,Store at room temperature; protect from light and moisture.
"Lumacaftor, a component of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector therapy, is a strong inducer of cytochrome P450 (CYP) 3A4 enzymes. Concurrent administration with norgestimate, a progestin component of oral contraceptives that is metabolized primarily by CYP3A4, can significantly reduce norgestimate plasma concentrations. This reduction may diminish the contraceptive efficacy and potentially lead to unintended pregnancy, as well as reduced therapeutic effects for other indications of norgestimate."
"Norgestimate, a progestin component of oral contraceptives, may induce the activity of UDP-glucuronosyltransferases (UGTs), particularly UGT1A1 and UGT2B7, which are involved in the glucuronidation and clearance of miglustat. This enzyme induction can decrease miglustat plasma concentrations, potentially reducing its therapeutic efficacy in treating Gaucher disease or Niemann-Pick type C disease. The clinical outcome could be diminished disease control, requiring dose adjustments or alternative therapy."
"Oxcarbazepine, a potent inducer of cytochrome P450 3A4 (CYP3A4) and uridine diphosphate glucuronosyltransferases (UGTs), significantly decreases the serum concentration of norgestimate by enhancing its hepatic metabolism. This metabolic induction converts norgestimate to less active metabolites, reducing its contraceptive efficacy. Clinically, this interaction may lead to unintended pregnancy in women using hormonal contraceptives containing norgestimate, as well as potential breakthrough bleeding or irregular menstrual cycles."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STIMATE vs DDAVP, answered by our medical review team.
STIMATE is a Antidiuretic Hormone Analog that works by Desmopressin acetate is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). It acts as a V2 receptor agonist in the renal collecting ducts, increasing water permeability and promoting water reabsorption, thereby reducing urine output. It also increases plasma levels of von Willebrand factor and factor VIII via V2 receptor stimulation on endothelial cells.. DDAVP is a Antidiuretic Hormone Analog that works by Synthetic analog of vasopressin; primarily activates V2 receptors in renal collecting ducts, increasing water reabsorption and concentrating urine.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STIMATE and DDAVP depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STIMATE is: Intranasal: 1 spray (1.5 mg) into one nostril, 1 hour prior to voiding or on awakening for bedwetting; maximum 2 sprays per day.. The standard adult dose of DDAVP is: Central diabetes insipidus: 0.1-0.4 mg orally every 12-24 hours or 0.5-1 mcg subcutaneously/intranasally every 12-24 hours. Nocturnal enuresis: 0.2-0.4 mg orally at bedtime. Hemophilia A/von Willebrand disease: 0.3 mcg/kg intravenous over 15-30 minutes or 300 mcg subcutaneously or 150 mcg intranasally (for >50 kg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STIMATE and DDAVP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STIMATE is classified as Category C. Pregnancy Category X. Desmopressin (STIMATE) is contraindicated in pregnancy due to risk of uterine contractions and potential fetal harm. First trimester: No adequate studies; the. DDAVP is classified as Category C. Category B: No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; risk cannot be excluded. Second and third trimester: No reported fetal har. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.